Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 11, 2008

Biological E. Gains Access to Production Technology from Heparinex and Choncept

  • Heparinex and Choncept entered into option and license agreements with Biological E. (BE), a biopharmaceutical company based in India. The agreement reportedly provides BE with an option for novel production technologies for both heparin- and chondroitin-related carbohydrate compounds.

    Heparinex is focused on development of novel recombinant synthesis of compounds for the anticoagulation market to replace the current heparin source of beef and other animal byproducts. Choncept works on the development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »